AGIOS PHARMACEUTICALS INC's ticker is AGIO and the CUSIP is 00847X104. A total of 187 filers reported holding AGIOS PHARMACEUTICALS INC in Q2 2021. The put-call ratio across all filers is 0.97 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $14,394,625 | -12.1% | 581,601 | +0.6% | 0.01% | 0.0% |
| Q2 2023 | $16,368,252 | +20.8% | 577,975 | -2.0% | 0.01% | +12.5% |
| Q1 2023 | $13,551,634 | -17.0% | 589,971 | +1.4% | 0.01% | -11.1% |
| Q4 2022 | $16,329,671 | -0.8% | 581,541 | -0.1% | 0.01% | -10.0% |
| Q3 2022 | $16,464,000 | +32.8% | 582,194 | +4.1% | 0.01% | +42.9% |
| Q2 2022 | $12,396,000 | -24.1% | 559,096 | -0.3% | 0.01% | -12.5% |
| Q1 2022 | $16,327,000 | -13.0% | 560,853 | -1.8% | 0.01% | 0.0% |
| Q4 2021 | $18,776,000 | -39.5% | 571,216 | -15.1% | 0.01% | -46.7% |
| Q3 2021 | $31,033,000 | -18.6% | 672,432 | -2.8% | 0.02% | -21.1% |
| Q2 2021 | $38,141,000 | +4.3% | 692,095 | -2.3% | 0.02% | -5.0% |
| Q1 2021 | $36,562,000 | +13.0% | 708,026 | -5.2% | 0.02% | 0.0% |
| Q4 2020 | $32,350,000 | +109.1% | 746,591 | +68.9% | 0.02% | +81.8% |
| Q3 2020 | $15,469,000 | -41.7% | 441,990 | -10.9% | 0.01% | -45.0% |
| Q2 2020 | $26,520,000 | +34.2% | 495,893 | -10.9% | 0.02% | +11.1% |
| Q1 2020 | $19,755,000 | -24.9% | 556,782 | +1.1% | 0.02% | +5.9% |
| Q4 2019 | $26,305,000 | +30.2% | 550,945 | -11.6% | 0.02% | +21.4% |
| Q3 2019 | $20,203,000 | -38.8% | 623,580 | -5.8% | 0.01% | -26.3% |
| Q2 2019 | $33,001,000 | +39.2% | 661,670 | +88.1% | 0.02% | +35.7% |
| Q1 2019 | $23,715,000 | +50.8% | 351,689 | +3.1% | 0.01% | +27.3% |
| Q4 2018 | $15,723,000 | -71.3% | 341,039 | -52.0% | 0.01% | -31.2% |
| Q3 2018 | $54,736,000 | -35.5% | 709,776 | -29.6% | 0.02% | -33.3% |
| Q2 2018 | $84,920,000 | +70.5% | 1,008,236 | +65.6% | 0.02% | 0.0% |
| Q1 2018 | $49,797,000 | +411.2% | 608,952 | +257.2% | 0.02% | +300.0% |
| Q4 2017 | $9,742,000 | -1.2% | 170,462 | +15.4% | 0.01% | -14.3% |
| Q3 2017 | $9,859,000 | -26.5% | 147,741 | -43.4% | 0.01% | -30.0% |
| Q2 2017 | $13,422,000 | +38.4% | 260,902 | +57.1% | 0.01% | +42.9% |
| Q1 2017 | $9,696,000 | +60.1% | 166,080 | +14.4% | 0.01% | +40.0% |
| Q4 2016 | $6,057,000 | -43.5% | 145,204 | -28.5% | 0.01% | -37.5% |
| Q3 2016 | $10,728,000 | +7.5% | 203,180 | -14.7% | 0.01% | +14.3% |
| Q2 2016 | $9,975,000 | +180.6% | 238,135 | +171.8% | 0.01% | +133.3% |
| Q1 2016 | $3,555,000 | +40.5% | 87,624 | +124.5% | 0.00% | +50.0% |
| Q4 2015 | $2,530,000 | -33.8% | 39,035 | -27.9% | 0.00% | -33.3% |
| Q3 2015 | $3,819,000 | -32.9% | 54,150 | +5.7% | 0.00% | -25.0% |
| Q2 2015 | $5,691,000 | -36.9% | 51,234 | -46.5% | 0.00% | -33.3% |
| Q1 2015 | $9,021,000 | -53.9% | 95,698 | -45.2% | 0.01% | -50.0% |
| Q4 2014 | $19,576,000 | +219.0% | 174,752 | +74.6% | 0.01% | +200.0% |
| Q3 2014 | $6,137,000 | +46.9% | 100,065 | +9.7% | 0.00% | +33.3% |
| Q2 2014 | $4,179,000 | +1158.7% | 91,226 | +974.8% | 0.00% | – |
| Q1 2014 | $332,000 | +87.6% | 8,488 | +14.2% | 0.00% | – |
| Q4 2013 | $177,000 | -50.6% | 7,430 | -42.2% | 0.00% | – |
| Q3 2013 | $358,000 | – | 12,844 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Eagle Health Investments LP | 431,413 | $12,558,000 | 3.09% |
| Casdin Capital, LLC | 2,090,000 | $60,840,000 | 2.73% |
| Rock Springs Capital Management LP | 2,665,275 | $77,586,000 | 1.95% |
| Bellevue Group AG | 4,129,292 | $120,204,000 | 1.40% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,177,374 | $34,273,000 | 1.05% |
| Altium Capital Management LP | 66,196 | $1,927,000 | 0.64% |
| ArrowMark Colorado Holdings LLC | 1,295,948 | $37,725,000 | 0.33% |
| FARALLON CAPITAL MANAGEMENT LLC | 1,333,012 | $38,804,000 | 0.19% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 21,500 | $707,000 | 0.16% |
| Virtus ETF Advisers LLC | 11,541 | $336,000 | 0.15% |